OAC-ALONE, the first randomized trial to test the efficacy of oral anticoagulation (OAC) alone against combined OAC and a single antiplatelet agent (APT) in patients with atrial fibrillation and stable coronary artery disease, was unable to establish noninferiority of OACs to dual therapy, according to data presented at the 30th annual TCT conference in San Diego.